{
    "nct_id": "NCT05046782",
    "official_title": "Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology",
    "inclusion_criteria": "Primary Objective Cohort\n\n* Treatment naïve patients with histologically confirmed clinically significant prostate cancer (defined as Gleason score > 3+4 and a maximum cancer core length of > 4mm (42)) with a clinical indication for prostate mpMRI for pre-treatment tumor detection and staging\n* Patients with anticipated clinical follow-up who are anticipated to undergo surgery at MD Anderson.\n\nSecondary Objective Cohort\n\n* Treatment naïve patients with histologically confirmed intermediate risk prostate cancer (defined as Gleason score > 3+4 and a maximum cancer core length of > 4mm (42)) with a clinical indication for prostate mpMRI, who are to undergo target selection for fusion guided biopsy.\n* Patients who are anticipated to undergo fusion guided biopsy at MD Anderson.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients who have already received androgen deprivation therapy or undergone prior surgery, radiotherapy or focal ablative therapies to the prostate\n* Patients whose weight exceeds 400 pounds\n* Patients allergic to gadolinium\n* Patients with pacemakers or other implantable devices or conditions that are a contraindication to MRI\n* Patients with conditions precluding MR imaging at 3T\n* Patients less than 18 years of age\n* Patients unable to provide informed consent\n* Patients unable to tolerate an endorectal coil\n* Patients who have undergone prostate biopsy less than 6 weeks prior to their MRI",
    "miscellaneous_criteria": "-"
}